Choosing anticancer drug targets in the postgenomic era.
Kaelin
W G
WG
Dana-Farber Cancer Institute, 44 Binney Street, Mayer 457, Boston, Massachusetts 02115, USA. william_kaelin@dfci.harvard.edu
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D015195:Drug Design; D018390:Gene Targeting; D016147:Genes, Tumor Suppressor; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D016160:Retinoblastoma Protein / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D011518:Proto-Oncogene Proteins; D016160:Retinoblastoma Protein